Top 10 Promising Stocks To Invest In 2014

It's no secret that oil and gas behemoth Chevron (NYSE: CVX  ) operates in a vast array of locations. Along with being a major player in the deepwater Gulf of Mexico, it's also the top dog in Australia's burgeoning LNG world. It's active in Sub-Saharan Africa and is the only major company working upstream in Saudi Arabia. It's also busy across Southeast Asia, and is trying to plumb hydrocarbons from Poland's shale formations.

But it's in South America, a continent on which it's figuratively been "snakebit" for years, that Chevron has made notable strides of late. The company has been attempting to fend off pesky legal challenges in Ecuador for about two decades, has seen its operations in Brazil called to a halt by an oil spill, and has evidenced a desire to begin operations in geologically promising but politically unstable Argentina.

Now, almost at once, there are tangible developments on all three of these fronts. Of course, progress in Ecuador, OPEC's tiniest member, doesn't imply new oil or gas discoveries or a pact for new exploratory efforts. It simply means that an ordeal of lawsuits and countersuits, all played out against a backdrop of apparently rampant fraud in the Ecuadorian legal system, may be coming to an end.

Top Telecom Stocks To Invest In 2015: Sapient Corporation(SAPE)

Sapient Corporation helps clients to leverage marketing and technology to transform their businesses in the United States and internationally. It operates in three segments: SapientNitro, Sapient Global Markets, and Sapient Government Services. The SapientNitro segment offers Web and interactive development, traditional advertising, media planning and buying, strategic planning and marketing analytics, and multi-channel commerce strategy and solutions, including a focus on mobile, and content and asset management strategies and solutions. This segment also provides integrated marketing and creative services, such as visual concept, design, and implementation through multiple media; brand building and direct response programs, audience segmentation, and profiling strategies; customer loyalty strategies; customer relationship strategy and implementation; customer lead generation and management; and integrated advertising campaigns. The Sapient Global Markets segment offers i ntegrated advisory, program management, analytics, technology, and operations services to capital and commodity markets. This segment also provides business and information technology strategy, process and system design, program management, custom development and package implementation, systems integration, and outsourced services to financial services and energy services markets. The Sapient Government Services segment offers digital marketing strategy and execution, program management, solution delivery, strategy, and communications and outreach services, as well as provides consulting, technology, and marketing services to the United States governmental agencies and non-governmental organizations. The company serves financial services, technology and communications, consumer, travel, automotive, energy services, government, health, and education sectors. Sapient Corporation was founded in 1990 and is headquartered in Boston, Massachusetts.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Sapient (Nasdaq: SAPE  ) , whose recent revenue and earnings are plotted below.

• [By CRWE]

  Sapient (NASDAQ:SAPE) reportedthat Alan J. Herrick, president and chief executive officer, and Joseph S. Tibbetts, Jr., senior vice president and chief financial officer, will present at the Sanford C. Bernstein Strategic Decisions Conference at The Waldorf Astoria in New York on Thursday, May 31, 2012 from 4:00 p.m. to 4:45 p.m. ET.

• [By Jayson Derrick]

  France-based Publicis Groupe (OTC: PUBGY) has agreed to acquire Sapient (NASDAQ: SAPE) for $3.7 billion, or $25 per share. Shares of Sapient surged to new 52-week highs of $24.73 before closing the day at $24.60, up 42.03 percent.

Top 10 Promising Stocks To Invest In 2014: Stryker Corporation(SYK)

Stryker Corporation, together with its subsidiaries, operates as a medical technology company worldwide. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment offers orthopaedic reconstructive (hip and knee) and trauma implant systems, as well as other related products. The MedSurg segment provides surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; and other related products. The Neurotechnology and Spine segment offers neurovascular products, spinal implant systems, and other related products. The company sells its products through local dealers and direct sales force to doctors, hospitals, and other healthcare facilities, as well as through third-party dealers and distributors in the United States, Europe, the Middle East, Africa, and Japan, Canada, the Pacific region, and the Latin America region. Stryker Corporat ion was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Advisors' Opinion:

• [By Dan Carroll and Max Macaluso, Ph.D.]

  What's Medtronic's response? The company plans to cut 230 jobs at its spine business and slash costs by 5% in order to compensate for the falling sales. With other companies in the industry also seeing spine revenue lagging --�Stryker's (NYSE: SYK  ) own spine sales fell 4% in 2012 -- will this measure be enough? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss this question and more in the video below.

• [By Steve Symington]

  Of course, Biomet is a privately held company, but it's safe to say that trials like this should have other publicly traded companies like Stryker (NYSE: SYK  ) , Zimmer (NYSE: ZMH  ) , and Johnson & Johnson (NYSE: JNJ  ) sweating bullets given their competing manually placed implants. It also doesn't help their case that Johnson & Johnson in March lost its first of 10,750 lawsuits over defective metal-on-metal hip implants, but you can bet MAKO can't wait to capitalize on the fallout with its own innovative offerings.

• [By Dan Carroll and Max Macaluso, Ph.D.]

  Buying into the Asian health-care scene isn't anything new. Stryker (NYSE: SYK  ) made waves earlier this year by purchasing Chinese spine and trauma firm Trauson for $764 million, and with China's health-care industry still in a state of transition, this is a potent grow opportunity for device firms. But is Panasonic's business worth all that much to buyers? Motley Fool contributor Dan Carroll and health-care analyst Max Macaluso discuss what you need to know in the following video.

Top 10 Promising Stocks To Invest In 2014: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Advisors' Opinion:

• [By Harry Boxer]

  HARRY:  It is.  More than 10 years, I visited 3-D systems and saw a demo, and it was like whoa.  They weren’t even public then.  Of late, SSYS (Stratasys), Proto Labs (PRLB), EX1; those are the four big ones in the industry.  There is a little buy-out tech company called Orvganovo (ONVO) that is now bio-printing organs for testing.

• [By Jake L'Ecuyer]

  Organovo Holdings (NYSE: ONVO) was also up, gaining 2.98 percent to $9.32. The rise in the shares may be attributed to Thursday's Computerworld Article on 3D printed liver coming in 2014.

• [By Monica Gerson]

  Organovo (NYSE: ONVO) shares jumped around 5% on Friday following an 11.7% rise on Thursday. Organovo reported positive results from a collaborative study using the company's 3D Human Liver Tissues on Thursday. Organovo shares gained 1.16% to $8.70 in the after-hours trading session.

Top 10 Promising Stocks To Invest In 2014: Curtiss-Wright Corporation (CW)

Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components and systems. It operates in three segments: Flow Control, Motion Control, and Metal Treatment. The Flow Control segment designs, manufactures, and distributes engineered products, including valves, pumps, motors, generators, instrumentation, shipboard systems, and control electronics that manage the flow of liquids and gases, generate power, provide electronic operating systems, and monitor or provide critical functions for naval defense, power generation, oil and gas, and general industrial markets. The Motion Control segment designs, develops, manufactures, and maintains mechanical actuation and drive systems, specialized sensors, motors, electronic controller units, and embedded computing components and control systems for ground defense, aerospace defense, commercial aerospace, and general industrial markets. The Metal Treatment segment provides metallu rgical processing services comprising shot peening, laser peening, specialty coatings and heat treating for commercial and defense aerospace, oil and gas, power generation, automotive, transportation, construction equipment, and miscellaneous metal working industries. The company operates primarily in the United States, the United Kingdom, and Canada. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Parsippany, New Jersey.

Advisors' Opinion:

• [By Marc Bastow]

  Engineered and advanced technical service products manufacturer Curtiss-Wright (CW) raised its quarterly dividend 30% to 13 cents per share, payable April 10 to shareholders of record as of March 27.
  CW Dividend Yield: 0.82%

• [By Alex Planes]

  In 1917, the two major aircraft manufacturers were forced into a patent pool that would offer modest licensing terms for prospective upstarts. By this point, the Wrights were out of the industry. Wilbur had died years earlier, and Orville had sold his stake to outside investors, leaving Curtiss with an easier path to the dominance previously denied him. The Wrights' reputation was badly damaged, and competition came to the industry despite their efforts. Years later, on the eve of the Great Depression, Curtiss gained a final measure of victory when his company and the Wrights' namesake business merged to become Curtiss-Wright (NYSE: CW  ) , which was at the time the largest aviation company in the United States. This company was also briefly a part of the Dow (from 1928 to 1930), making it the first aviation component in the index's history.

• [By Shauna O'Brien]

  On Monday, Curtiss-Wright Corp. (CW) announced that it has completed its acquisition of Arens Controls, LLC for $98 million.

  The newly acquired business will operate under CW’s Controls segment. David C. Adams, President and CEO of CW noted: “The acquisition of Arens complements our previous acquisitions of Williams Controls and PG Drives, further strengthening and growing Curtiss-Wright’s existing industrial controls business.”

  “This is another step toward our vision of being the supplier of choice for operator control subsystems and critical drivetrain components in specialty vehicles. As a leading designer and manufacturer of critical vehicle controls technologies, Arens’ complementary products and long-standing customer relationships position Curtiss-Wright for increased penetration within the commercial and off-road vehicle markets. Additionally, this acquisition allows us to leverage our global manufacturing footprint to create margin expansion opportunities,” Adams added.

  Curtiss-Wright shares were down 46 cents, or 1.00%, during Monday morning trading. The stock is up 39% YTD.

Top 10 Promising Stocks To Invest In 2014: Biodel Inc (BIOD)

Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).

The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.

Advisors' Opinion:

• [By Monica Gerson]

  Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.

  First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.

• [By Roberto Pedone]

  One under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.

  If you take a look at the chart for Biodel, you'll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.

  Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Promising Stocks To Invest In 2014: Pruksa Real Estate PCL (PS)

Pruksa Real Estate PCL is a Thailand-based company engaged in the development of commercial buildings and residential housing. It serves both local and overseas markets. The Company offers single-detached houses, townhouses and condominiums under the names of Baan Pruksa, Pruksa Ville, The Connect, The Plant Citi, Passorn, Pruksa Village, The Seed, IVY, The Plant City, Urbano, Tree condo, ChapterOne and Be You, among others. The Company develops residential housing projects mainly in Bangkok and the surrounding areas. It also has projects in Nakhorn Pathom, Chonburi and Phuket, as well as overseas projects in India, Vietnam, and Maldives. As of December 31, 2012, it operated 141 projects and had five direct subsidiaries, including Kaysorn Construction Company Limited, Putthachart Estate Company Limited, Phanalee Estate Company Limited, Pruksa Overseas Company Limited and Pruksa International Company Limited. Advisors' Opinion:

• [By amigobulls@twitter]

  Twitter currently trades at a Last Twelve Months (LTM) Price to Sales (PS) ratio of 27, which translates to astronomical valuations. Consider a comparison with Facebook which generates about 10 times the revenue and still grows at a healthy 60 odd percent. Facebook trades at an LTM PS multiple of 19. Here one should note that Facebook also delivered a net profit margin of 27% in Q2 vs Twitter's loss margin of 46% and has nearly 5 times Twitter's active users.

Top 10 Promising Stocks To Invest In 2014: Fibria Celulose SA (FBR)

Fibria Celulose S.A. (Fibria), formerly Votorantim Celulose e Papel S.A., incorporated on July 25, 1941, is a producer of market pulp. During the year ended December 31, 2010, Fibria produced 5,054 kilotons of eucalyptus pulp (including 50.0% of the pulp production of Veracel). The Company also produces coated and uncoated paper, carbonless paper and thermal paper at its Piracicaba paper mill, located in the State of Sao Paulo with an annual production capacity of 190 kilotons. During 2010, it produced 115 kilotons of paper products and recorded consolidated net revenues. Fibria produces bleached eucalyptus kraft pulp at three pulp mills, the Aracruz pulp mill located in the State of Espirito Santo, which has an annual production capacity of 2.3 million tons; the Tres Lagoas pulp mill located in the State of Mato Grosso do Sul, which has an annual production capacity of 1.3 million tons, and the Jacarei pulp mill located in the State of Sao Paulo, which has an annual production capacity of 1.1 million tons. The Company has a 50% interest in Veracel, which owns and operates a pulp mill in the municipality of Eunapolis, State of Bahia, with an annual production capacity of 1.1 million tons.

Pulp

Fibria produces bleached eucalyptus kraft pulp from planted eucalyptus trees. Bleached eucalyptus kraft pulp is a range of hardwood pulp. Eucalyptus is a hardwood tree, and its pulp has short fibers and is generally suited to manufacturing tissue, coated and uncoated printing and writing paper and coated packaging boards. Short fibers are optimal for manufacturing wood-free paper with good printability, smoothness, brightness and uniformity. Market pulp is the pulp sold to producers of paper products. Kraft pulp is pulp produced in a chemical process using sulphate. During 2010, it produced 5,054 kilotons of pulp (including 50.0% of the pulp production of Veracel).

Paper

During 2010, Fibria produced 115 kilotons of paper. The Company produced coated printing an! d writing paper, which is a coated woodfree paper used for promotional materials, folders, internal sheets and cover of magazines, books, tabloids, inserts and mailing; uncoated printing and writing paper, which is a uncoated woodfree paper in reels and sheets; carbonless paper, which is used to produce multi-copy forms, POS, invoices and other applications in place of traditional carbon paper, and thermal paper, which is traditionally used in fax machines; POS, bar code labels, toll tickets, water and gas bills and receipts for automated teller machines (ATMs) and credit card machines. It manufactures thermal paper products with technology licensed byOji Paper Co., Ltd (Oji Paper).

The Company competes with APRIL, Arauco, APP, Georgia Pacific, CMPC, Sodra, Stora Enso, Weyerhaeuser and Suzano.

Advisors' Opinion:

• [By Seth Jayson]

  Fibria Celulose (NYSE: FBR  ) reported earnings on July 24. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended June 30 (Q2), Fibria Celulose met expectations on revenues and missed expectations on earnings per share.